Background
==========

Osteosarcoma (OS) frequently occurs in teenagers and young adults and causes 20% of all primary bone cancers \[[@b1-medscimonit-24-5914]\]. Despite the success of neoadjuvant chemotherapy followed by surgical resection for osteosarcoma, the survival rate of pediatric patients is still low, and their progression-free survival was reported to be about 23 months \[[@b2-medscimonit-24-5914]\]. Therefore, discovery of potential diagnostic and effective therapeutic targets used for the treatment of OS is an urgent issue for the development of new OS drugs.

There are dozens of antineoplastic drugs being tested in hundreds of clinical trials for the treatment of osteosarcoma retrieved from the clinicaltrials.gov website \[[@b3-medscimonit-24-5914]\]. Most clinical candidates involve several crucial cell signaling pathways, particularly protein kinase inhibitors \[[@b4-medscimonit-24-5914]\]. In addition, the drugs that interacted with DNA, referred to as cytotoxic agents or specific ribozyme inhibitors, are also thought to account for a large proportion in these osteosarcoma clinical trials. Thus, we collected a series of antitumor targets obtained from corresponding experimental drugs for the treatment of OS, as well as the potential therapeutic targets of these drugs for the first step in this study.

MicroRNAs (miRNAs) are small noncoding regulatory RNAs 22--25 nucleotides in length, which widely participate in a number of biological processes \[[@b5-medscimonit-24-5914]\]. The miRNAs dysfunction that ties many pathological conditions together involves obvious change in several biological processes, including cell proliferation, apoptosis, cell cycle, migration, and invasion \[[@b6-medscimonit-24-5914]\]. Although this imbalance of miRNAs expression level cannot be considered as the primary cause for various diseases, the expression profiles analysis of miRNAs on a genome-wide scale could contribute to the discovery of new targets, especially for complicated tumor diseases. For example, various recently reported miRNAs suppressed OS cell proliferation, cell cycle progression, and apoptosis, such as miR-20a \[[@b7-medscimonit-24-5914]\], miR-26a \[[@b8-medscimonit-24-5914]\], miR-100 \[[@b4-medscimonit-24-5914]\], miR-124 \[[@b9-medscimonit-24-5914]\], miR-126 \[[@b10-medscimonit-24-5914]\], miR-195 \[[@b11-medscimonit-24-5914]\], miR-205 \[[@b12-medscimonit-24-5914]\], and miR-491 \[[@b13-medscimonit-24-5914]\]. Based on these findings, we searched for dozens of various potential targets of OS by querying the validated targets from Tarbase \[[@b14-medscimonit-24-5914]\], a miRNAs target database.

Although many possible targets used for OS therapy had been reported \[[@b15-medscimonit-24-5914]\] and many bioinformatics databases such as the Target Central Resource Database (TCRD) have been used to uncover possible targets of OS \[[@b16-medscimonit-24-5914]\], the most promising targets for clinical use remain to be discovered. In the present study, we explored novel effective targets of OS by network analysis focusing on potential targets collected in as many different ways as possible, and subsequently investigated the underlying mechanism by use of MTT assay and flow cytometry. Our results may lay the foundation for development of new OS drugs.

Material and Methods
====================

Cell culture
------------

The 4 human OS cell lines -- LM7, SaOS-2, U2OS, and MG-63 -- were purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China), and cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Beyotime Biotechnology, Shanghai, China). These 4 cancer cell lines were then incubated at 37°C in a humidified atmosphere containing 5% CO~2~.

Network construction
--------------------

The potential targets used for the treatment of OS were selected from 4 different sources: (1) The possible targets retrieved from DrugBank \[[@b17-medscimonit-24-5914]\] by searching for 28 clinical drugs used for OS ([Table 1](#t1-medscimonit-24-5914){ref-type="table"}); (2) The possible kinase targets as shown in [Table 2](#t2-medscimonit-24-5914){ref-type="table"} retrieved from the TCRD database \[[@b16-medscimonit-24-5914]\] (*<https://pharos.nih.gov/idg/index>*); (3) The possible targets obtained from Tarbase database on the basis of microRNAs involved with OS validated by the dbDEMC 2.0 database \[[@b18-medscimonit-24-5914]\] ([Table 3](#t3-medscimonit-24-5914){ref-type="table"}); and (4) The possible targets obtained from Tarbase database on the basis of microRNAs involved with OS validated by recent papers ([Table 4](#t4-medscimonit-24-5914){ref-type="table"}). In addition, these targets listed above were imported into the Biological Information Annotation Databases for the molecular function and biological process annotation. To facilitate scientific interpretation of complex relationships between OS targets and signaling pathways, network analysis was performed. The "Target-Pathway" network was generated by Cytoscape (*<http://www.cytoscape.org/>*) \[[@b19-medscimonit-24-5914]\], which is an open-source software for visualizing complex networks and integrating these with any type of attribute data.

The MTT assay
-------------

Compound NVP-TNKS656 was purchased from SelleckChem. The anti-proliferation activities of prepared compounds were evaluated as described in previous reports \[[@b20-medscimonit-24-5914]\]. The 4 OS cells -- LM7, SaOS-2, U2OS, and MG-63 (5000 cells/well) -- were seeded in a 96-well plate, and then incubated with compound (0.5 μM) for 0, 12, 24, or 36 h. Subsequently, 10 μL MTT solution (5 mg/mL; Beyotime Institute of Biotechnology, Haimen, China) was added to each well, followed by incubation for another 4 h. After the supernatant was removed, 100 μL dimethyl sulfoxide was added to each well. The absorbance was detected at 570 nm with a microplate reader.

Apoptosis analysis
------------------

MG-63 cells were seeded in 12-well plates, at 1×10^5^ cells/well, and incubated for 12 h. Cells were treated with this compound at 4 different concentrations (10, 50, 100, and 200 nM) for 24 h. The cell apoptosis was detected using an Annexin-V-FITC Apoptosis Detection kit (KeyGEN, BioTECH, Nanjing, China) by flow cytometry, according to the manufacturer's instructions. FlowJo software was used for the data analysis (Leonard Herzenberg, Stanford University, USA). Cells staining negative in the presence of Annexin-V and PI were defined as viable cells.

Cell cycle analysis
-------------------

MG-63 cells were seeded in 6-well plates (1×10^6^ cells/well) and incubated at 37°C for 12 h. The target cells were treated with the compound (0.5 μM) for 24 h. After treatment, cells were collected and fixed with 75% ethanol at −20°C overnight. In the next step, cells were washed with PBS followed by centrifugation, and incubated with 5 μL (10 mg/mL) RNase and 2.5 μL (5 mg/mL) propidium iodide (Beyotime Institute of Biotechnology, Haimen, China) for 30 min. Flow cytometry analysis was performed using CellQuest software (BD Bioscience, USA) and FlowJo software was used for the data analysis (Leonard Herzenberg, Stanford University, USA).

Statistical analysis
--------------------

All experiments were performed at least 3 times. Values are expressed as the mean ± standard deviation. Significant differences among the groups were determined by one-way analysis of variance using Origin8.6 (OriginLab Corporation, Northampton, MA, USA).

Results
=======

Drug-target search
------------------

While osteosarcoma has been referred to as an "orphan cancer" with no known driver oncogenes \[[@b21-medscimonit-24-5914]\], it actually was reported to include many useful biomarkers. In order to detect the potential targets for new drugs, we first focused on the clinically known drugs for OS therapy and sorted out 28 monomers (small molecules and monoclonal antibody, as presented in [Table 1](#t1-medscimonit-24-5914){ref-type="table"}), as well as seeking corresponding targets of these drugs by searching in the DrugBank database \[[@b17-medscimonit-24-5914]\]. Secondly, it is well known that there are hundreds of bioinformatic databases on various areas of molecular biology released in the past 10 years \[[@b22-medscimonit-24-5914]\], forming the basis of "big data". Among them, Target Central Resource Database (TCRD, *<https://pharos.nih.gov/idg/index>*) is mainly curated interrelated data on unstudied and understudied drug targets. We collected 31 potential OS protein kinase targets ([Table 2](#t2-medscimonit-24-5914){ref-type="table"}) by searching the TCRD database, taking into consideration their vital function of signaling pathways. Thirdly, a great many powerful studies indicated that miRNAs can effectively regulate OS progression \[[@b23-medscimonit-24-5914]--[@b25-medscimonit-24-5914]\], leading to the assumption that they should possess 1 or more common drug targets. Thus, searched for possible OS targets of miRNAs related to OS by querying high degree of confidence (Pred.Score ≥0.9) targets in Tarbase \[[@b14-medscimonit-24-5914]\]. We found 171 OS targets.

Network construction and analysis
---------------------------------

The 171 potential OS targets were imported into Database for Annotation, Visualization, and Integrated Discovery (DAVID) for mapping these targets into the KEGG pathway database.As shown in [Figure 1](#f1-medscimonit-24-5914){ref-type="fig"}, only a few key cell signaling pathways were manually retained, while there were many mapping items presented in the output of the DAVID website. The obtained results showed that the primary molecular mechanism of clinical drugs in [Table 1](#t1-medscimonit-24-5914){ref-type="table"} were the MAPK signaling pathway and the PI3K-Akt signaling pathway. Most of the targets validated from TCRD are shown in [Table 2](#t2-medscimonit-24-5914){ref-type="table"}, but there were still several apparent protein targets such as PRKACB, MKNK2, and PAK5 that are closely involved with the MAPK signaling pathway and the ErbB signaling pathway. In addition, it is obvious that half of these miRNAs can also be mapped into these signaling pathways. Searching for new targets around these classical signaling pathways takes considerable effort, but selecting novel targets seemed more meaningful for the development of anti-OS drugs. A series of studies showing that miRNAs can perturb OS could reveal more potential targets. The localized network at the right part of [Figure 1](#f1-medscimonit-24-5914){ref-type="fig"} shows that the 3 targets -- TNKS2, ZNF367, and BIF4G2 -- are also new possible targets in the further target validation stage.

TNSK2 inhibitor decreases OS cell proliferation
-----------------------------------------------

The present study evaluated the anti-proliferative activity effects of TNSK2 inhibitor on 4 OS cells (LM7, SaOS-2, U2OS, and MG-63) using the MTT assay. As shown in [Figure 2](#f2-medscimonit-24-5914){ref-type="fig"}, the target compound effectively inhibited the proliferation of all the tested OS cells at the concentration of 0.5 *μ*M, and also exhibited more potent inhibition over time. Among them, the inhibitory activity against MG63 cells was most potent.

TNSK2 inhibitor induced G2/M phase arrest, and induced OS cell apoptosis in a dose-dependent manner
---------------------------------------------------------------------------------------------------

The TNSK2 inhibitor obviously induced G2/M phase arrest of MG63 cells at the concentration of 100 nM ([Figure 3](#f3-medscimonit-24-5914){ref-type="fig"}). It was apparent that the percentage of MG63 cells in the G2/M phase was also markedly increased (62% cells) when compared with the blank control. [Figure 4](#f4-medscimonit-24-5914){ref-type="fig"} shows that TNSK2 inhibitor induced MG63 cell apoptosis in a dose-dependent manner. The percentage of apoptotic cells determined by flow cytometry analysis was obviously increased with increasing dose (10, 50, 100, and 200 nM) of test compound. The apoptosis rate of MG63 osteosarcoma cells was 2.73%, 3.87%, 5.89%, and 6.97%, respectively. Moreover, the early apoptosis rate of MG63 cells was 12.9%, even at the low concentration of NVP-TNKS656 (10 nM, [Figure 4A](#f4-medscimonit-24-5914){ref-type="fig"}).

Discussion
==========

All the potential targets are presented in detail in [Tables 1](#t1-medscimonit-24-5914){ref-type="table"}[](#t2-medscimonit-24-5914){ref-type="table"}[](#t3-medscimonit-24-5914){ref-type="table"}--[4](#t4-medscimonit-24-5914){ref-type="table"}. In order to build the network more conveniently, the 28 drugs in [Table 1](#t1-medscimonit-24-5914){ref-type="table"} were named as "clinical drugs". For the TCRD targets in [Table 2](#t2-medscimonit-24-5914){ref-type="table"}, we attempted to connect them with the supposition "TCRD_Obtained". The dataset in [Tables 3](#t3-medscimonit-24-5914){ref-type="table"} and [4](#t4-medscimonit-24-5914){ref-type="table"} could be employed for the establishment of the "miRNA-Targets" network ([Figure 1](#f1-medscimonit-24-5914){ref-type="fig"}). As mentioned previously, the network of the signaling pathway is a great source of protein targets in OS cells, as well as other common cancer cells such as EGFR \[[@b26-medscimonit-24-5914]\] located in the ErbB signaling pathway as a tumor marker or valid target used for the treatment of non-small cell lung cancer (NSCLC).

TNSKS2, which is a poly (ADP-ribose) polymerase (PARP) that adds ADP-ribose polymers onto target proteins \[[@b20-medscimonit-24-5914]\]. In fact, as blockbuster PARP inhibitors such as Olaparib \[[@b27-medscimonit-24-5914]\], Rucaparib \[[@b28-medscimonit-24-5914]\], and Niraparib \[[@b29-medscimonit-24-5914]\] have been approved as novel anticancer agents in the last 2 years, the development of PARP inhibitors has been regarded as the new direction of anticancer drugs. Moreover, TNKS2 was closely correlated with the Wnt/β-catenin pathway, and the inhibition of TNKS2 can overcome resistance to PI3K/AKT inhibitors in cancer therapy \[[@b30-medscimonit-24-5914]\]. However, there are only a few TNKS2 inhibitors reported to be the preclinical phase so far. Based on the information above, we surmise that TNKS2 or function-similar protein might be regarded as a class of novel targets used for the treatment of OS. In this next section, we demonstrate the effectiveness for the inhibition of TNSK2 by preliminary biological assay.

Compound NVP-TNKS656 ([Figure 5](#f5-medscimonit-24-5914){ref-type="fig"}) was reported to be a highly potent and selective tankyrase inhibitor with the IC~50~ value of 6 nM against Tankyrase 2 (TNKS2). Tankyrase 2 is regarded as a key druggable node in the Wnt pathway involved with carcinogenesis, and the 4-methoxybenzoyl-piperidine moiety of this compound is responsible for the inhibition of TNSK2. Actually, the idea of tankyrases as drug targets was put forward as early as 2013 \[[@b31-medscimonit-24-5914]\], and most studies of tankyrase inhibitors \[[@b32-medscimonit-24-5914]--[@b34-medscimonit-24-5914]\] have proved them to be effective for specific cancers, possibly including OS. The MTT assay used in this study to a certain extent verified the potential of TNKS2 inhibitor, at least at the OS cell level.

In order to further investigate OS cell suppression by tankyrase inhibition, compound NVP-TNKS656 was chosen for further cell cycle and induced apoptosis assay. The G2/M checkpoint prevents cells from entering mitosis when unrepaired DNA damage was generated in cells \[[@b35-medscimonit-24-5914]\]. Consistent with previous studies, several papers \[[@b30-medscimonit-24-5914],[@b36-medscimonit-24-5914],[@b37-medscimonit-24-5914]\] on TNSK inhibitors reported that downregulation of the cell cycle regulator Cyclin D1 could explain the G2/M cell cycle, particular the "IWR-1" just published in the *Cancer Letters* journal \[[@b30-medscimonit-24-5914]\]. Additionally, we also performed a cell apoptosis experiment to investigate whether the inhibitory activity of NVP-TNKS656 against MG63 cells was related to cell apoptosis. These 2 results provide further evidence that TNSK2 inhibitors have potential for the treatment of OS, and TNSK2 might be a promising target for the design of novel OS drugs.

Conclusions
===========

Osteosarcoma (OS) is one of the most common human cancers, but there is no clear and effective antitumor target, even for those known clinical candidates used for the treatment of OS, which is very challenging for the development of anti-osteosarcoma drugs. In the present study, we attempted to find more promising targets that might be used for OS therapy by construction and analysis of the "Target-Pathway" network. The obtained results show that tankyrase 2 (TNKS2), a multifunctional poly (ADP-ribose) polymerase (PARP), might be a very potential protein target for the treatment of osteosarcoma. An *in vitro* MTT assay proved that it is an available option against OS by targeting the TNKS2 protein. Subsequently, cell cycle and apoptosis assay by flow cytometry showed the TNKS2 inhibitor can obviously induce cell cycle arrest, apoptosis, and mitotic cell death. The present study shows a new direction directing for the development of anti-osteosarcoma drugs and provides a combined medication scheme for the treatment of OS.
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![Antiproliferative activity of NVP-TNKS656 against the 4 common osteosarcoma cells at the increase of incubating time: 0, 12, 24, and 36 h after dosing. (**A**) LM7 cell; (**B**) SaOS-2 cell; (**C**) U2OS cell; (**D**) MG-63 cell.](medscimonit-24-5914-g002){#f2-medscimonit-24-5914}

![Comparison of the cell cycle distribution after drug treatment determined by flow cytometry using MG-63 osteosarcoma cells. Light blue bar: blank control; deep blue bar: NVP-TNKS656 at the concentration of 0.1 μM.](medscimonit-24-5914-g003){#f3-medscimonit-24-5914}

![MG-63 cells treated with different concentrations of compound NVP-TNKS656 for 48 h were collected and cell apoptosis was analyzed by flow cytometry. (**A**) 10 nM; (**B**) 50 nM; (**C**) 100 nM; (**D**) 200 nM.](medscimonit-24-5914-g004){#f4-medscimonit-24-5914}

![The chemical structure of NVP-TNKS656 as highly selective tankyrase 2 (TNKS2) inhibitor.](medscimonit-24-5914-g005){#f5-medscimonit-24-5914}

###### 

The main clinical drugs that exclude cytotoxic agents used for the treatment of osteosarcoma and their important targets at the clinical Phase I, II, III, and IV currently.

  No.                                                   Drugs             Targets at the DrugBank database                
  ----------------------------------------------------- ----------------- ----------------------------------------------- --------------------------------------------------------
  1                                                     Zoledronic acid   Farnesyl pyrophosphate synthase                 FDPS
  Geranylgeranyl pyrophosphate synthase                 GGPS1                                                             
  2                                                     Leucovorin        Thymidylate synthase                            TYMS
  3                                                     Afatinib          Vascular endothelial growth factor receptor-2   KDR
  4                                                     Rapamycin         Mammalian target of rapamycin                   MTOR
  5                                                     Sorafenib         Serine/threonine-protein kinase B-raf           BRAF
  Vascular endothelial growth factor receptor 2         KDR                                                               
  Mast/stem cell growth factor receptor Kit             KIT                                                               
  6                                                     Methotrexate      Dihydrofolate reductase                         DHFR
  7                                                     Pembrolizumab     Programmed cell death protein 1                 PDCD1
  8                                                     Etoposide         DNA topoisomerase 2-alpha                       TOP2A
  9                                                     Avelumab          programmed death-ligand 1                       PDCD1L1
  10                                                    Eribulin          Tubulin beta-1 chain                            TUBB1
  11                                                    Pazopanib         Vascular endothelial growth factor receptor 1   Flt1
  Vascular endothelial growth factor receptor 2         KDR                                                               
  Platelet-derived growth factor receptor alpha         PDGFRA                                                            
  Platelet-derived growth factor receptor beta          PDGFRB                                                            
  12                                                    Lenvatinib        Vascular endothelial growth factor receptor 1   Flt1
  Vascular endothelial growth factor receptor 2         KDR                                                               
  Vascular endothelial growth factor receptor 3         FLT4                                                              
  Fibroblast growth factor receptor 1                   FGFR1                                                             
  Fibroblast growth factor receptor 2                   FGFR2                                                             
  Fibroblast growth factor receptor 3                   FGFR3                                                             
  Fibroblast growth factor receptor 4                   FGFR4                                                             
  13                                                    Cabozantinib      Hepatocyte growth factor receptor               MET
  Vascular endothelial growth factor receptor 2         KDR                                                               
  Proto-oncogene tyrosine-protein kinase receptor Ret   RET                                                               
  14                                                    Regorafenib       More than 15 protein kinases                    --[\*](#tfn1-medscimonit-24-5914){ref-type="table-fn"}
  15                                                    Nivolumab         Programmed cell death protein 1                 PDCD1
  16                                                    Paclitaxel        Apoptosis regulator Bcl-2                       BCL2
  Tubulin beta-1 chain                                  TUBB1                                                             
  17                                                    Lexatumumab       Death receptor 5                                TNFRSF10B
  18                                                    Irinotecan        DNA topoisomerase 1                             TOP1
  19                                                    Gefitinib         Epidermal growth factor receptor                EGFR
  20                                                    RO4929097         Gamma secretase                                 APH1A/B
  21                                                    Larotrectinib     Tropomyosin kinase                              Trk
  22                                                    Ipilimumab        Cytotoxic T-lymphocyte protein 4                CTLA4
  23                                                    Tanespimycin      Heat shock protein 90                           HSP90
  24                                                    Erlotinib         Epidermal growth factor receptor                EGFR
  25                                                    Alvocidib         Cyclin-dependent kinase                         CDK
  26                                                    Cixutumumab       Insulin-like growth factor 1 receptor           IGF1R
  27                                                    Romidepsin        Histone deacetylase 1                           HDAC1
  Histone deacetylase 2                                 HDAC2                                                             
  28                                                    Abemaciclib       Cyclin-dependent kinase 4                       CDK4
  Cyclin-dependent kinase 6                             CDK6                                                              

Means too many kinases to list in this table.

###### 

The main potential kinase targets retrieved from the Target Central Resource Database for the treatment of osteosarcoma at the Tclin[\*](#tfn2-medscimonit-24-5914){ref-type="table-fn"} and Tchem[\*\*](#tfn3-medscimonit-24-5914){ref-type="table-fn"} development/druggability levels.

  No.   Name                                                                          Gene
  ----- ----------------------------------------------------------------------------- ---------
  1     Cyclin-dependent kinase 11B                                                   CDK11B
  2     Serine/threonine-protein kinase PAK 5                                         PAK5
  3     Dual specificity tyrosine-phosphorylation-regulated kinase 1B                 DYRK1B
  4     Casein kinase II subunit alpha'                                               CSNK2A2
  5     Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase   PKMYT1
  6     Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform      PHKA1
  7     Cyclin-dependent kinase-like 3                                                CDKL3
  8     Cyclin-dependent kinase 17                                                    CDK17
  9     Cyclin-dependent kinase-like 1                                                CDKL1
  10    Serine/threonine-protein kinase Nek5                                          NEK5
  11    SRSF protein kinase 3                                                         SRPK3
  12    Serine/threonine-protein kinase RIO1                                          RIOK1
  13    Phosphorylase b kinase gamma catalytic chain, liver/testis isoform            PHKG2
  14    Atypical kinase COQ8B, mitochondrial                                          COQ8B
  15    Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform   PHKG1
  16    Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma                        PIP4K2C
  17    Dual specificity protein kinase CLK4                                          CLK4
  18    Serine/threonine-protein kinase 17A                                           STK17A
  19    Calcium/calmodulin-dependent protein kinase type 1D                           CAMK1D
  20    Cyclin-dependent kinase 14                                                    CDK14
  21    Serine/threonine-protein kinase PRP4 homolog                                  PRPF4B
  22    Microtubule-associated serine/threonine-protein kinase 2                      MAST2
  23    MAP kinase-interacting serine/threonine-protein kinase 2                      MKNK2
  24    Serine/threonine-protein kinase tousled-like 2                                TLK2
  25    Dual specificity protein kinase CLK3                                          CLK3
  26    Dual specificity tyrosine-phosphorylation-regulated kinase 2                  DYRK2
  27    Thymidine kinase 2, mitochondrial                                             TK2
  28    Serine/threonine-protein kinase Nek7                                          NEK7
  29    Phosphatidylinositol 4-kinase alpha                                           PI4KA
  30    cAMP-dependent protein kinase catalytic subunit beta                          PRKACB
  31    Protein kinase C theta type                                                   PRKCQ

These targets have activities in DrugCentral database (approved drugs) with known mechanism of action;

these targets have activities in ChEMBL or DrugCentral.

###### 

The key microRNAs with downregulated expression in osteosarcoma samples from the dbDEMC 2.0 database.

  No.   microRNAs    Targets form Tarbase (Pred.Score ≥0.9 & Gene name)
  ----- ------------ -------------------------------------------------------------------------
  1     miR-1        TNKS2, SPRED1, SRSF1
  2     miR-126      BRWD3, JARID2, SCD, NPAS2, HIPK2
  3     miR-133a     NUP160, SGPP1, COL8A1, FAM160B1, CELF1, TSPAN18, MAP3K2
  4     miR-133b     RB1CC1, CELF1, FTL, MCL1
  5     miR-142-3p   TCEB3, TEX2, KDELR2, IRAK1
  6     miR-144      SNTB2, EIF4G2, ZNF367, ZNF800, CEP350, DCP2, TNKS2
  7     miR-150      MTCH2, LDLR, PERP
  8     miR-195      CCNE1, WEE1, FBXW7, IPO7, E2F3, SKI, AGO1, SON, CDC27, CDC42SE2, NUFIP2
  9     miR-205-5p   CCNJ, CBX1, SNW1
  10    miR-206      GJA1, TNKS2, SRSF9, MMD, GPD2, EFNB2, SERP1, IFT52, TWF1, ZNF264, PGD
  11    miR-223      PARP1, SCARB1, RASGRP1
  12    miR-451      PFAS
  13    miR-486-5p   ST6GALNAC6, ZNF367
  14    miR-497      RAF1, RUNX2, IGF1R, MAP2K1

###### 

The microRNAs reported for the inhibitory activities against osteosarcoma in these recent papers.

  No.   microRNAs                                 Targets form Tarbase (Pred.Score ≥0.9 & Gene name)
  ----- ----------------------------------------- ---------------------------------------------------------------------------------------------------
  1     miR-20a \[[@b7-medscimonit-24-5914]\]     GINM1, RUFY2, C2CD2, TNKS2, PTPN4, SIK1, EFCAB14, RASL11B, ZNF367
  2     miR-26a \[[@b8-medscimonit-24-5914]\]     ZBTB18, TOB1, REEP3, MSMO1, OSBPL11, DDX3X, NXPE3, HOXA9, ZFHX4, PDHX, EIF4G2
  3     miR-100 \[[@b4-medscimonit-24-5914]\]     NONE
  4     miR-124 \[[@b9-medscimonit-24-5914]\]     VAMP3, CD164, RAB10, TARBP1, HIPK3, LAMC1, RRAGD, PTBP1, SLC35F5, QSER1, DCAF16, STK35, CGN, AGO1
  5     miR-125a \[[@b38-medscimonit-24-5914]\]   MFHAS1, SEMA4C, RORA, FAM118A, KPNA6, ZC3H7B, CDK16
  6     miR-126 \[[@b10-medscimonit-24-5914]\]    BRWD3, JARID2, SCD, NPAS2, HIPK2
  7     miR-195 \[[@b11-medscimonit-24-5914]\]    CCNE1, WEE1, FBXW7, IPO7, E2F3, SKI, AGO1, SON, CDC27, CDC42SE2, NUFIP2
  8     miR-205 \[[@b12-medscimonit-24-5914]\]    CCNJ, CBX1, SNW1
  9     miR-216a \[[@b39-medscimonit-24-5914]\]   GATAD2B
  10    miR-382 \[[@b40-medscimonit-24-5914]\]    NONE
  11    miR-491 \[[@b13-medscimonit-24-5914]\]    GATAD2B, DIRAS1, ANKRD52, IGF2BP1
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